Journal article
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial
Abstract
Abstract
PAM50-defined breast cancer intrinsic subtypes and risk-of-relapse (ROR) scores are prognostic and predictive of endocrine therapy and some chemotherapy. We investigated the prognostic and predictive effect of PAM50 classifications by chemotherapy type. NCIC CTG MA.21 randomized 2,104 patients to doxorubicin, cyclophosphamide, and paclitaxel (AC/T); dose-intense cyclophosphamide, epirubicin, and flurouracil (CEF); or dose-dense, …
Authors
Liu S; Chapman J-AW; Burnell MJ; Levine MN; Pritchard KI; Whelan TJ; Rugo HS; Albain KS; Perez EA; Virk S
Journal
Breast Cancer Research and Treatment, Vol. 149, No. 2, pp. 439–448
Publisher
Springer Nature
Publication Date
1 2015
DOI
10.1007/s10549-014-3259-1
ISSN
0167-6806